Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.25-5.27%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GLUE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 70.3 | 123.7 | 75.6 | 0.0 | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 179.4 | 141.5 | 121.6 | 111.3 | 85.1 | 57.2 | 24.0 |
| Operating Income | (150.8) | (54.2) | (81.1) | (143.3) | (112.4) | (72.9) | (28.0) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 20.9 | 14.5 | 11.0 | 8.3 | 3.9 | (1.1) | (7.9) |
| EBT, Incl. Unusual Items | (129.9) | (39.7) | (70.1) | (135.0) | (108.5) | — | — |
| Income Tax Expense | 1.0 | (1.1) | 2.6 | 0.3 | 0.0 | — | — |
| Net Income | |||||||
| Net Income | (130.9) | (38.6) | (72.7) | (135.4) | (108.5) | (74.0) | (35.9) |
| Per Share | |||||||
| Basic EPS | (1.29) | — | — | — | — | — | — |
| Diluted EPS | (1.21) | — | — | — | — | — | — |
| Revenue per Share | 0.65 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 101.8 | 83.1 | 73.9 | 51.4 | 47.2 | 25.0 | — |
| Diluted Weighted Avg Shares | 108.6 | 83.1 | 73.9 | 51.4 | 47.2 | 25.0 | — |
| Supplemental | |||||||
| EBIT | (150.8) | (54.2) | (81.1) | (143.3) | (112.4) | (72.9) | (28.0) |
| Effective Tax Rate | -0.8% | — | — | -0.3% | 0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.